Elder to hire 1,000 reps for rural-India sales effort; Shire narrows U.K. distribution for some products;

  @FiercePharma: Wall Street sees Astellas nabbing OSI for up to $4.3 billion. Article | Follow @FiercePharma   

 The H1N1 flu pandemic is as severe as influenza pandemics in 1957 and 1968 and remains a threat to healthy young adults, John Mackenzie, the Australian who heads the World Health Organization's Emergency Committee, said Wednesday. Report

> India's Elder Pharmaceuticals aims to recruit 1,000 new sales and marketing employees over the next two months to launch a push into untapped rural markets. Report

> Shire has unveiled plans to use three exclusive wholesalers in the U.K. for such products as the bone drug Fosrenol and Alzheimer's remedy Reminyl. Report

> Indian drugmaker Ranbaxy Laboratories is voluntarily recalling at the retail level two lots of an oral suspension form of an antibiotic containing amoxicillin and clavulanate potassium. Report

> Russian Prime Minister Vladimir Putin approved a deal to sell a private insulin plant in the country to Sanofi-Aventis. Report

> A federal judge in Delaware has refused to dismiss a lawsuit accusing AstraZeneca of anticompetitive practices involving the heart drug Toprol-XL. Report

> Shares of Santarus slumped a day after the drug maker disclosed a U.S. federal judge ruled five patents for stomach drug Zegerid are invalid. Report

> Sigma Pharmaceuticals, the Australian drugmaker that lost half its market value after reporting a record loss last month, says CEO Elmo de Alwis has resigned. Report

Biotech News

  @FierceBiotech: Positive MS data may thwart Icahn's plans for Genzyme. Story | Follow @FierceBiotech    

 @JohnCFierce: Agios gets $130M upfront in Celgene deal--now that's real money. | Follow @JohnCFierce

> Struggling Cell Therapeutics chops 36 workers. Story

> Third Rock raising $400 million venture fund for biotech "game-changers." Article

> Agios scores $130 million upfront from ambitious Celgene pact. Report

> Cambridge startup lands $25 million round for genetic sequencing play. Story

Manufacturing News

> Pfizer, GSK present at FDA's continuous processing symposium. Report

> Pall bullish on disposable filters, bioreactors. News

> Cold-chain solutions a must by 2014. Report

> Pharma industry, J&J drop in public opinion poll. Story

Vaccines News

> Oral vax provides big assist to patients with severe COPD. Item

> Personalized cancer vax heads to trial. Report

> HPV vax may prevent other cancers. News

> Dynavax shares spike on promising Heplisav data. Story

 And Finally... Do estrogen's effects on women's minds and bodies depend heavily upon when they first start taking it? Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.